ReviewWorld journal of gastroenterology2017
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
Review in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 71 citations in OpenAlex.
- Analysis of misdiagnosis of pancreatic acinar cell carcinoma with significantly elevated alpha-fetoprotein: a case report and literature review.Frontiers in oncology · 2026Article
- Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC.Journal of translational medicine · 2025Article
- Pancreatic Acinar Cell Carcinoma: Demographics, Treatment, and Survival Outcomes, A Retrospective Population-Based Study.Journal of gastrointestinal cancer · 2025Article
- Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.Annals of surgical oncology · 2025Article
- Pediatric pancreatic acinar cell carcinoma with a non-canonical BRAF-KMT2C fusion and a classic SND1-BRAF fusion: a case report and literature review.BMC pediatrics · 2025Review
- A case of pancreatic acinar cell carcinoma implantation in multiple branches of the pancreatic duct without main tumor continuity: a rare case report.Journal of gastrointestinal oncology · 2024Article
- Article
- Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.Japanese journal of clinical oncology · 2024Review
- Single-cell mapping identifies MSICancer cell · 2023Article
- RareWorld journal of clinical cases · 2023Article
- A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX.Surgical case reports · 2023Article
- Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.World journal of gastroenterology · 2022Review
- Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.Clinical case reports · 2022Article
- "Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms.Virchows Archiv : an international journal of pathology · 2022Article
- Transabdominal ultrasonographic diagnosis of relatively rare pancreatic neoplasms.Journal of medical ultrasonics (2001) · 2022Review
- Imaging and Clinicopathological Features of Acinar Cell Carcinoma.Frontiers in oncology · 2022Review
- Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.JCO precision oncology · 2022Article
- Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature.Clinical Medicine Insights. Oncology · 2022Article
- Article
- Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic carcinomas with acinar differentiation are rare, accounting for 1%-2% of adult pancreatic tumors; they include pancreatic acinar cell carcinoma (PACC), pancreatoblastoma, and carcinomas of mixed differentiation. Patients with PACC have a prognosis better than pancreatic ductal adenocarcinomas but worse than pancreatic neuroendocrine tumors. Reports of overall survival range from 18 to 47 mo. A literature review on PACCs included comprehensive genomic profiling and whole exome sequencing on a series of more than 70 patients as well as other diagnostic studies including immunohistochemistry. Surgical resection of PACC is the preferred treatment for localized and resectable tumors. The efficacy of adjuvant treatment is unclear. Metastatic PACCs are generally not curable and treated with systemic chemotherapy. They are moderately responsive to chemotherapy with different regimens showing various degrees of response in case reports/series. Most of these regimens were developed to treat patients with pancreatic ductal adenocarcinomas or colorectal adenocarcinomas. Review of PACC's molecular profiling showed a number of gene alterations such as:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.